Clinical trials: Pulmonary Disease (COPD), Chronic Obstructive
- Condition Pulmonary Disease (COPD), Chronic Obstructive
- Funder type Industry (pharma, biotech, devices)
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a…
- Trial name
- NCT01627327
- Testing
- fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
A Feasibility Study of Wearable Device in Assessing Respiratory Condition Change of Patients With Exacerbation of COPD
The study will include daily SenseGuard measurement of patients hospitalized with exacerbations of COPD. from admission to discharge.
- Trial name
- NCT05153122
- Testing
- SenseGuard
- Where
- 2 sites in Germany, Israel
- Volunteers
- 15 people
- Sponsor
- NanoVation
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL).
- Trial name
- NCT06175065
- Testing
- RLS-0071
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- ReAlta Life Sciences, Inc.
Asthma
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
- Trial name
- NCT02753712
- Testing
- Fluticasone/Formoterol BAI, Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
- Where
- 16 sites in Australia, New Zealand and 3 more
- Volunteers
- 105 people
- Sponsor
- Mundipharma Research Limited
Asthma, Chronic Obstructive Pulmonary Disease
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone Easyhaler to achieve and maintain asthma or COPD control.
- Trial name
- SUNNY (NCT03755544)
- Where
- Germany
- Volunteers
- 231 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma, Chronic Obstructive Pulmonary Disease
Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
The study is to evaluate the percentage of patients with asthma or COPD achieving disease control
- Trial name
- SPRINT (NCT02419872)
- Testing
- Marketed antagonists
- Where
- 141 sites in Croatia, Denmark and 8 more
- Volunteers
- 1,743 people
- Sponsor
- Teva Pharmaceuticals Europe
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00144911
- Testing
- Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
- Where
- 97 sites in United States, Canada
- Volunteers
- 740 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity and mortality throughout the world, being the fourth leading cause of death in the world.
- Trial name
- NCT02680639
- Testing
- BiPAP Synchrony ventilator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Philips Respironics
Smoking Cessation
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
- Trial name
- NCT00285012
- Testing
- Varenicline Tartarate
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 504 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Adipose Derived Cells for Chronic Obstructive Pulmonary Disease
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed with chronic obstructive pulmonary…
- Trial name
- NCT02041000
- Testing
- Adipose Derived Stem Cells
- Where
- United States
- Sponsor
- Bioheart, Inc.
Pulmonary Disease, Chronic Obstructive
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT06527144
- Testing
- 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation
- Where
- 28 sites in China
- Volunteers
- 240 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IV multi-center, randomized, open-label, cross-over, placebo study in subjects with Chronic Obstructive Pulmonary Disease (COPD) to compare inhaler-specific preference attributes of two inhalers - ELLIPTA dry…
- Trial name
- NCT02786927
- Testing
- Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
- Where
- 22 sites in United States
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Obstructive Pulmonary Disease
Study in Patients With COPD
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
- Trial name
- NCT00215423
- Testing
- Formoterol Fumarate
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Chronic Obstructive Pulmonary Disease (COPD)
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
- Trial name
- NCT04169529
- Testing
- Reveal LINQ
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Airway Disease
Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation
This study is a prospective, single-center feasibility study to acquire more knowledge regarding the NeuRx DPS and develop a routine in the optimal pacing of the diaphragm with this system during the weaning period from…
- Trial name
- NCT02411383
- Testing
- NeuRx Diaphragm Pacing System
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- Synapse Biomedical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.